DCPH News and Press, Deciphera Pharmaceuticals Inc. From 02/09/21

Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2020 Earnings Conference Call February 09, 2021, 16:30 PM ET Company Participants Jen Robinson - Vice President, Investor Relations Steven Hoerter - President and Chief Executive Officer Daniel Martin - Chief Commercial Officer Matthew Sherman - Chief...

Image source: The Motley Fool. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q4 2020 Earnings Call Feb 9, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2020 Earnings Call...

Deciphera Pharmaceuticals (DCPH): Q4 GAAP EPS of -$1.10 beats by $0.07.Revenue of $19.49M beats by $1.07M.Cash, equivalents and marketable securities were $561.3M.Top-line results in INTRIGUE Phase 3 Study of QINLOCK in patients with second-line GIST expected in 2H 2021.Pipeline candidates, V...

- Fourth Quarter 2020 QINLOCK® Net Revenue of $19.5 Million and Full Year 2020 QINLOCK Net Revenue of $39.5 Million - - Top-line Results in INTRIGUE Phase 3 Study of QINLOCK in Patients with Second-line GIST Expected in the Second Half of 2021 - - Pipeline Candida...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day on February 11, 2021 at 11:00 AM ET. The conference will be held ...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, February 9, 2021. In connection with the earnings release, Deciphera’s management team will host a live conference call and w...

The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with this event. For further details see: Deciphera Pharmaceuticals (DCPH) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

Deciphera Pharmaceuticals (DCPH) intends to expand the market and clinical potential of ripretinib (QINLOCK®) in 2021, the company said in an announcement, issued in conjunction with its presentation at the 39th Annual J.P. Morgan Virtual Healthcare Conference.CEO of Deciphera, Stev...

- Top-line Data for INTRIGUE Pivotal Phase 3 Study of QINLOCK® in Patients with Second-line GIST Expected in the Second Half of 2021 - - Potential European Medicines Agency Approval of QINLOCK for Patients with Fourth-line GIST in the Second Half of 2021 - - Company Plannin...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 AM ET. A live webcast of the event will be available on...